# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Biodesix (NASDAQ:BDSX) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.09) by 1...
Craig-Hallum analyst Bill Bonello initiates coverage on Biodesix (NASDAQ:BDSX) with a Buy rating and announces Price Target ...
TD Cowen analyst Dan Brennan initiates coverage on Biodesix (NASDAQ:BDSX) with a Buy rating and announces Price Target of $2.8.
Biodesix (NASDAQ:BDSX) reported quarterly losses of $(0.14) per share which met the analyst consensus estimate. This is a 41.67...
Lake Street initiates coverage on Biodesix (NASDAQ:BDSX) with a Buy rating and announces Price Target of $3.
These presentations highlight advancements in liquid biopsy technologies that detect cell free DNA (cfDNA) and the clinical val...
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 200 points on Friday. The Dow...